Cantargia AB
Cantargia AB develops IL‑1RAP‑targeting antibodies for cancer and autoimmune diseases. Phase II candidate nadunolimab (CAN04) in pancreatic, NSCLC, TNBC trials; phase I CAN10 treats systemic sclerosis and myocarditis.
Headquarters: Sweden (SWE)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 23
- HQ: Lund
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.